HK1116165A1 - - Google Patents
Info
- Publication number
- HK1116165A1 HK1116165A1 HK08105432.7A HK08105432A HK1116165A1 HK 1116165 A1 HK1116165 A1 HK 1116165A1 HK 08105432 A HK08105432 A HK 08105432A HK 1116165 A1 HK1116165 A1 HK 1116165A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disorders
- cyanoindol
- benzofuran
- carbamoyl
- butyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01113647 | 2001-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1116165A1 true HK1116165A1 (uk) | 2008-12-19 |
Family
ID=8177643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04108857A HK1066003A1 (en) | 2001-06-19 | 2004-11-10 | Polymorphic forms of 1-'4 (5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
HK08105432.7A HK1116165A1 (uk) | 2001-06-19 | 2008-05-16 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04108857A HK1066003A1 (en) | 2001-06-19 | 2004-11-10 | Polymorphic forms of 1-'4 (5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Country Status (30)
Country | Link |
---|---|
US (15) | US7381726B2 (uk) |
EP (1) | EP1397357B9 (uk) |
JP (3) | JP4624667B2 (uk) |
KR (1) | KR20040012922A (uk) |
CN (2) | CN101139345B (uk) |
AR (1) | AR034595A1 (uk) |
AT (1) | ATE437871T1 (uk) |
AU (1) | AU2002320822B2 (uk) |
BR (1) | BR0210495A (uk) |
CA (16) | CA2782519A1 (uk) |
CY (1) | CY1109447T1 (uk) |
CZ (2) | CZ304471B6 (uk) |
DE (1) | DE60233133D1 (uk) |
DK (1) | DK1397357T3 (uk) |
EC (1) | ECSP044943A (uk) |
EE (1) | EE05454B1 (uk) |
ES (1) | ES2330314T3 (uk) |
HK (2) | HK1066003A1 (uk) |
HU (1) | HU229601B1 (uk) |
IL (2) | IL159426A0 (uk) |
MX (1) | MXPA03011723A (uk) |
MY (1) | MY151087A (uk) |
NZ (1) | NZ530642A (uk) |
PL (1) | PL208708B1 (uk) |
PT (1) | PT1397357E (uk) |
RU (1) | RU2303598C2 (uk) |
SK (2) | SK288162B6 (uk) |
UA (1) | UA76758C2 (uk) |
WO (1) | WO2002102794A2 (uk) |
ZA (1) | ZA200400329B (uk) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA76758C2 (uk) * | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину |
DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
DE10326940A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
US9708300B2 (en) | 2011-03-20 | 2017-07-18 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for its preparation |
CN102219783B (zh) * | 2011-05-05 | 2013-07-03 | 天津市汉康医药生物技术有限公司 | 盐酸维拉佐酮及其组合物 |
US9505744B2 (en) | 2011-11-23 | 2016-11-29 | Assia Chemical Industries Ltd. | Solid state forms of vilazodone and vilazodone hydrochloride |
US20140378472A1 (en) | 2011-12-12 | 2014-12-25 | Ranbaxy Laboratories Limited | Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof |
WO2013153492A2 (en) | 2012-04-12 | 2013-10-17 | Alembic Pharmaceuticals Limited | Process for the preparation of vilazodone hydrochloride and its amorphous form |
EP2838894A1 (en) * | 2012-04-16 | 2015-02-25 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline vilazodone hydrochloride |
WO2013164794A1 (en) * | 2012-05-04 | 2013-11-07 | Ranbaxy Laboratories Limited | Crystalline forms of vilazodone hydrochloride |
US20150126525A1 (en) | 2012-05-11 | 2015-05-07 | Dr. Reddy's Laboratories Limited | Crystalline forms of vilazodone hydrochloride and vilazodone free base |
WO2013175361A1 (en) | 2012-05-24 | 2013-11-28 | Ranbaxy Laboratories Limited | Process for the preparation of vilazodone hydrochloride |
CN102702180A (zh) * | 2012-05-25 | 2012-10-03 | 吉林三善恩科技开发有限公司 | 一种维拉佐酮有机药物共晶及其制备方法 |
US8835635B2 (en) * | 2012-06-05 | 2014-09-16 | Symed Labs Limited | Amorphous form of vilazodone hydrochloride substantially free of crystalline forms |
WO2013182946A2 (en) | 2012-06-06 | 2013-12-12 | Ranbaxy Laboratories Limited | Process for the preparation of vilazodone hydrochloride |
CA2876741A1 (en) | 2012-06-13 | 2013-12-19 | Apotex Inc. | Forms of vilazodone and processes for the preparation thereof |
WO2014028473A1 (en) | 2012-08-13 | 2014-02-20 | Assia Chemical Industries Ltd. | New salts of vilazodone and solid state forms thereof |
WO2014049609A2 (en) * | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Novel salts of vilazodone |
WO2014049612A2 (en) * | 2012-09-27 | 2014-04-03 | Msn Laboratories Limited | Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts |
WO2014064715A2 (en) | 2012-10-22 | 2014-05-01 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for preparing thereof |
CN103772368B (zh) * | 2012-10-24 | 2016-08-03 | 杭州和泽医药科技有限公司 | 盐酸维拉佐酮iv晶型的制备方法及其应用 |
CN103772367B (zh) * | 2012-10-24 | 2016-05-25 | 杭州和泽医药科技有限公司 | 盐酸维拉佐酮v晶型的制备方法及其应用 |
WO2014087428A1 (en) * | 2012-12-07 | 2014-06-12 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of vilazodone and intermediates thereof |
CN102977083A (zh) * | 2012-12-17 | 2013-03-20 | 南京海纳医药科技有限公司 | 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法 |
WO2014178013A1 (en) | 2013-04-30 | 2014-11-06 | Ranbaxy Laboratories Limited | Vilazodone impurities, process for their preparation, and their use as reference standards |
WO2014199313A1 (en) | 2013-06-12 | 2014-12-18 | Lupin Limited | Substantially pure vilazodone hydrochloride and a process thereof |
EP2824104A1 (en) | 2013-07-12 | 2015-01-14 | Sandoz AG | Process for the preparation of form III of Vilazodone hydrochloride |
WO2015019256A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Pharmaceutical composition of vilazodone and processes of preparation thereof |
WO2015019237A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Pharmaceutical composition of vilazodone |
WO2015037010A1 (en) * | 2013-09-13 | 2015-03-19 | Symed Labs Limited | Preparation of vilazodone hydrochloride crystalline form iv |
CN104610238A (zh) * | 2013-11-01 | 2015-05-13 | 北京英科博雅科技有限公司 | 一种维拉佐酮盐酸盐iii晶型新的制备方法 |
ITMI20131839A1 (it) * | 2013-11-06 | 2015-05-07 | Dipharma Francis Srl | Co-cristallo di un farmaco antidepressivo |
WO2015102019A2 (en) * | 2013-12-30 | 2015-07-09 | Msn Laboratories Private Limited | Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride |
CN105017233A (zh) * | 2014-04-23 | 2015-11-04 | 天津药物研究院 | 一种盐酸维拉佐酮晶体、其制备方法、药物组合物和用途 |
CN105820157B (zh) * | 2015-01-09 | 2021-05-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸维拉佐酮晶型及其制备方法 |
CN106518854A (zh) * | 2016-09-21 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 一种盐酸维拉佐酮晶型ⅳ的制备方法 |
TR201702103A2 (tr) | 2017-02-13 | 2018-08-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilazodon hi̇droklorürün tablet formlari |
TR201702104A2 (tr) | 2017-02-13 | 2018-08-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vi̇lazodon hi̇droklorür farmasöti̇k bi̇leşi̇mleri̇ |
CN107098889A (zh) * | 2017-03-17 | 2017-08-29 | 北京万全德众医药生物技术有限公司 | 盐酸维拉佐酮药物晶型ⅲ的制备方法 |
CN109503560A (zh) * | 2017-09-14 | 2019-03-22 | 北京万全德众医药生物技术有限公司 | 盐酸维拉佐酮ⅺ晶型的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US532241A (en) * | 1895-01-08 | Computing-machine | ||
US1294526A (en) * | 1917-09-21 | 1919-02-18 | Gerhard Nicolaas Vis | Manufacture of sodium carbonate and ammonium sulfate from bisulfate of soda. |
DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
US5521241A (en) * | 1994-08-30 | 1996-05-28 | W. R. Grace & Co.-Conn. | Styrene copolymer-based plastisol containing glycidyl methacrylate |
DE19514567A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Benzofurane |
TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
AU7591001A (en) | 2000-07-13 | 2002-01-30 | Hydrogen Energy America Llc | Method and apparatus for controlled generation of hydrogen by dissociation of water |
UA76758C2 (uk) * | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину |
US7384020B2 (en) * | 2006-06-30 | 2008-06-10 | Amtek System Co., Ltd. | Supporting frame structure |
-
2002
- 2002-05-06 UA UA2004010354A patent/UA76758C2/uk unknown
- 2002-06-05 AU AU2002320822A patent/AU2002320822B2/en not_active Expired
- 2002-06-05 CA CA2782519A patent/CA2782519A1/en not_active Abandoned
- 2002-06-05 EP EP02754627A patent/EP1397357B9/en not_active Expired - Lifetime
- 2002-06-05 CA CA2782868A patent/CA2782868A1/en not_active Abandoned
- 2002-06-05 JP JP2003506267A patent/JP4624667B2/ja not_active Expired - Lifetime
- 2002-06-05 HU HU0400236A patent/HU229601B1/hu unknown
- 2002-06-05 AT AT02754627T patent/ATE437871T1/de active
- 2002-06-05 CA CA2782623A patent/CA2782623A1/en not_active Abandoned
- 2002-06-05 SK SK16-2004A patent/SK288162B6/sk unknown
- 2002-06-05 CZ CZ2004-26A patent/CZ304471B6/cs not_active IP Right Cessation
- 2002-06-05 MX MXPA03011723A patent/MXPA03011723A/es active IP Right Grant
- 2002-06-05 CA CA2782521A patent/CA2782521A1/en not_active Abandoned
- 2002-06-05 CA CA2782494A patent/CA2782494A1/en not_active Abandoned
- 2002-06-05 CA CA2683040A patent/CA2683040C/en not_active Expired - Fee Related
- 2002-06-05 CA CA2782628A patent/CA2782628A1/en not_active Abandoned
- 2002-06-05 EE EEP200400019A patent/EE05454B1/xx unknown
- 2002-06-05 CA CA2782857A patent/CA2782857A1/en not_active Abandoned
- 2002-06-05 CA CA2782865A patent/CA2782865A1/en not_active Abandoned
- 2002-06-05 CA CA2782761A patent/CA2782761A1/en not_active Abandoned
- 2002-06-05 CA CA2782517A patent/CA2782517A1/en not_active Abandoned
- 2002-06-05 IL IL15942602A patent/IL159426A0/xx unknown
- 2002-06-05 CN CN2007101802298A patent/CN101139345B/zh not_active Expired - Lifetime
- 2002-06-05 CZ CZ2013-141A patent/CZ305220B6/cs not_active IP Right Cessation
- 2002-06-05 DK DK02754627T patent/DK1397357T3/da active
- 2002-06-05 CA CA2782791A patent/CA2782791A1/en not_active Abandoned
- 2002-06-05 RU RU2004100824/04A patent/RU2303598C2/ru active
- 2002-06-05 CN CNB028122267A patent/CN100384841C/zh not_active Expired - Lifetime
- 2002-06-05 KR KR10-2003-7016261A patent/KR20040012922A/ko not_active Application Discontinuation
- 2002-06-05 US US10/481,270 patent/US7381726B2/en not_active Expired - Lifetime
- 2002-06-05 NZ NZ530642A patent/NZ530642A/en not_active IP Right Cessation
- 2002-06-05 ES ES02754627T patent/ES2330314T3/es not_active Expired - Lifetime
- 2002-06-05 PT PT02754627T patent/PT1397357E/pt unknown
- 2002-06-05 CA CA2782862A patent/CA2782862A1/en not_active Abandoned
- 2002-06-05 WO PCT/EP2002/006153 patent/WO2002102794A2/en active Application Filing
- 2002-06-05 BR BR0210495-4A patent/BR0210495A/pt not_active Application Discontinuation
- 2002-06-05 CA CA2451028A patent/CA2451028C/en not_active Expired - Fee Related
- 2002-06-05 CA CA2782515A patent/CA2782515A1/en not_active Abandoned
- 2002-06-05 DE DE60233133T patent/DE60233133D1/de not_active Expired - Lifetime
- 2002-06-05 CA CA2782615A patent/CA2782615A1/en not_active Abandoned
- 2002-06-05 PL PL364576A patent/PL208708B1/pl unknown
- 2002-06-05 SK SK5028-2012A patent/SK288334B6/sk unknown
- 2002-06-13 MY MYPI20022214 patent/MY151087A/en unknown
- 2002-06-19 AR ARP020102289A patent/AR034595A1/es not_active Application Discontinuation
-
2003
- 2003-12-17 IL IL159426A patent/IL159426A/en active IP Right Grant
-
2004
- 2004-01-15 ZA ZA2004/00329A patent/ZA200400329B/en unknown
- 2004-01-15 EC EC2004004943A patent/ECSP044943A/es unknown
- 2004-11-10 HK HK04108857A patent/HK1066003A1/xx not_active IP Right Cessation
-
2008
- 2008-04-28 US US12/110,704 patent/US7834020B2/en not_active Expired - Lifetime
- 2008-05-16 HK HK08105432.7A patent/HK1116165A1/xx not_active IP Right Cessation
-
2009
- 2009-09-25 US US12/566,835 patent/US7981894B2/en not_active Expired - Fee Related
- 2009-09-30 CY CY20091101023T patent/CY1109447T1/el unknown
-
2010
- 2010-02-08 JP JP2010025038A patent/JP5411734B2/ja not_active Expired - Lifetime
- 2010-02-08 JP JP2010025039A patent/JP5714824B2/ja not_active Expired - Lifetime
- 2010-11-12 US US12/945,272 patent/US8193195B2/en not_active Expired - Lifetime
- 2010-11-12 US US12/945,260 patent/US20110183994A1/en not_active Abandoned
-
2011
- 2011-04-12 US US13/085,117 patent/US8318744B2/en not_active Expired - Lifetime
- 2011-05-04 US US13/100,911 patent/US20110294824A1/en not_active Abandoned
- 2011-05-04 US US13/100,948 patent/US8236804B2/en not_active Expired - Lifetime
-
2012
- 2012-10-23 US US13/658,088 patent/US8927552B2/en not_active Expired - Fee Related
-
2013
- 2013-09-19 US US14/032,183 patent/US8673921B2/en not_active Expired - Lifetime
-
2014
- 2014-05-30 US US14/291,931 patent/US8921375B2/en not_active Expired - Fee Related
- 2014-11-21 US US14/549,779 patent/US9624204B2/en not_active Expired - Lifetime
-
2017
- 2017-03-09 US US15/454,642 patent/US20170182037A1/en not_active Abandoned
-
2019
- 2019-03-18 US US16/355,982 patent/US20190343831A1/en not_active Abandoned
-
2020
- 2020-12-01 US US17/108,101 patent/US20210251986A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1116165A1 (uk) | ||
NO20061562L (no) | Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ] -4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter | |
TW200503713A (en) | Novel compounds | |
MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
EP1411943A4 (en) | METHODS FOR TREATING COGNITIVE DISORDERS OR MENOPAUSE DISORDERS BY D-THREO METHYLPHENIDATE | |
AU2003249983A1 (en) | Piperidines useful for the treatment of central nervous system disorders | |
EP1773345A4 (en) | NON-IMIDAZOLE TERTIARY AMINES USED AS HISTAMINE 3 RECEPTOR INHIBITORS IN THE TREATMENT OF COGNITIVE DISORDERS AND SLEEP, OBESITY AND OTHER CNS DISORDERS | |
HUP0104838A2 (hu) | Gyomor-bélrendszer rendellenességeinek kezelésére szolgáló 4-(amino-metil)-piperidin-benzamidok, eljárás előállításukra és intermedierjeik | |
HUP0501017A3 (en) | Methods and compositions for treatment of central nervous system disorders | |
NO20073113L (no) | Indenylderivater og anvendelse derav for behandling av neurologiske lidelser | |
HUP0200284A2 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them | |
BR0208040A (pt) | Derivados de benzofuran-2-carboxamidas substituìdas | |
HK1041880A1 (en) | Compounds and methods for treatment of asthma, allergy and inflammatory disorders. | |
NO20070878L (no) | Dimere piperidinderivater | |
IL160615A0 (en) | Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders | |
MY130725A (en) | Composition and method for treating allergic diseases | |
AU2002315485A1 (en) | Compositions and methods for the treatment of body weight disorders, including obesity | |
HUP0401161A3 (en) | Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride, process for their preparation and pharmaceutical compositions containing the crystalline forms | |
IL158630A0 (en) | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
ZA200308631B (en) | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders. | |
PL364392A1 (en) | Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof | |
IL158629A0 (en) | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
IL158700A0 (en) | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
NO20055514L (no) | Piperazinderivater og deres anvendelse ved behandling av neurologiske og psykiatriske sykdommer | |
BR9909368A (pt) | Composições e métodos para o tratamento de dermatite atópica, angioedema e outros distúrbios usando anti-histaminas e glicocorticóides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20220604 |